Kadcyla, a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones, has been approved by the U.S. Food and Drug Administration.
Researchers believe the drug may offer a clear advantage over older drugs because it delivers more medication with fewer side effects due to a binding chemical.
The FDA approved the new treatment for about 20% of breast cancer patients with a more aggressive form of the disease that is typically less responsive to hormone therapy. Researchers reported last year that patients treated with Kadcyla lived 9.6 months before death of the spread of their disease, compared with a little more than six months for patients treated with other standard drugs. Read the full details here:
Despite many medical advances breast cancer claims thousands of lives every year. Vigilant exams, regular mammography and treatment breakthroughs like this will continue to increase the survival rate of breast cancer.
If you or someone you love has been injured by a defective product, drug, or malpractice, call the professionals at Crandall & Pera Law for a free case evaluation.